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Abstract 35 
The human adenovirus (HAdV) phylogenetic tree is diverse, divided across seven species and comprising 36 
over 100 individual types. Species D HAdV are rarely isolated with low rates of pre-existing immunity, 37 
making them appealing for therapeutic applications. Several species D vectors have been developed as 38 
vaccines against infectious diseases where they induce robust immunity in pre-clinical models and early 39 
phase clinical trials. However, many aspects of the basic virology of species D HAdV, including their basic 40 
receptor usage and means of cell entry, remain understudied. 41 
Here, we investigated HAdV-D49, which previously has been studied for vaccine and vascular gene 42 
transfer applications. We generated a pseudotyped HAdV-C5 presenting the HAdV-D49 fiber knob 43 
protein (HAdV-C5/D49K). This pseudotyped vector was efficient at infecting cells devoid of all known 44 
HAdV receptors, indicating HAdV-D49 uses an unidentified cellular receptor. Conversely, a pseudotyped 45 
vector presenting the fiber knob protein of the closely related HAdV-D30 (HAdV-C5/D30K), differing in 46 
four amino acids to HAdV-D49, failed to demonstrate the same tropism. These four amino acid changes 47 
resulted in a change in isoelectric point of the knob protein, with HAdV-D49K possessing a basic apical 48 
region compared to a more acidic region in HAdV-D30K. Structurally and biologically we demonstrate 49 
that HAdV-D49 knob protein is unable to engage CD46, whilst potential interaction with CAR is 50 
extremely limited by extension of the DG loop. HAdV-C5/49K efficiently transduced cancer cell lines of 51 
pancreatic, breast, lung, oesophageal and ovarian origin, indicating it may have potential for oncolytic 52 
virotherapy applications, especially for difficult to transduce tumour types.  53 
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Importance 54 
Adenoviruses are powerful tools experimentally and clinically. To maximise efficacy, the development of 55 
serotypes with low pre-existing levels of immunity in the population is desirable. Consequently, 56 
attention has focussed on those derived from species D, which have proven robust vaccine platforms. 57 
This widespread usage is despite limited knowledge in their basic biology and cellular tropism. 58 
We investigated the tropism of HAdV-D49, demonstrating it uses a novel cell entry mechanism that 59 
bypasses all known HAdV receptors. We demonstrate, biologically, that a pseudotyped HAdV-C5/D49K 60 
vector efficiently transduces a wide range of cell lines, including those presenting no known adenovirus 61 
receptor. Structural investigation suggests that this broad tropism is the result of a highly basic 62 
electrostatic surface potential, since a homologous pseudotyped vector with a more acidic surface 63 
potential, HAdV-C5/D30K, does not display a similar pan-tropism. Therefore, HAdV-C5/D49K may form a 64 
powerful vector for therapeutic applications capable of infecting difficult to transduce cells.   65 
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Introduction: 66 
Human adenoviruses are divided into seven species, A-G(1). These non-enveloped, icosahedral viruses 67 
have garnered significant interest as therapeutic vectors since they can be grown and purified to high 68 
titers, and because the double-stranded DNA genome is readily amenable to genetic modification, 69 
enabling the overexpression of therapeutic transgenes(2, 3). Similar techniques can also be applied to 70 
genetically alter the virus structural genes, creating modified viral tropisms which are retained by 71 
progeny virions after replication. 72 
Clinically, adenoviruses have been developed as vectors for gene therapy, vaccines, and as oncolytic 73 
virotherapies(1, 4, 5). However, efficacy in these applications can be hampered by pre-existing immunity 74 
against the therapeutic vector in the population resulting from prior exposure to the wild type 75 
pathogen. Such pre-existing immunity is likely to reduce the therapeutic index of such systems, due to 76 
rapid and efficient removal of the engineered therapeutic agent by the reticuloendothelial system(6, 7). 77 
This is especially relevant where the therapeutic is based on the most commonly studied species C 78 
adenovirus, human adenovirus type 5 (HAdV-C5), where neutralising antibodies are found in ~90% of 79 
patients from sub-Saharan Africa and ~30% of a Scottish patient cohort(8, 9). 80 
A promising means to circumvent pre-existing immunity is through the development of viruses with 81 
naturally low seroprevalence rates as therapeutic agents. For example, vaccines have been developed 82 
using chimpanzee adenoviruses which have little to no seroprevalence in humans. However, it appears a 83 
significant percentage of some populations may still harbour some immunity to chimpanzee 84 
adenoviruses, as observed in a cohort from China(10). 85 
Most attempts to develop adenoviruses with low seroprevalence have focused on those derived from 86 
species B or D, due to their comparative rarity(5, 9, 11). The most clinically advanced of these are HAdV-87 
D26 and Enadenotucirev (formerly ColoAd1)(12). Enadenotucirev was developed by evolution of a panel 88 
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of different adenovirus strains to select for recombinants with rapid replication in tumour cells. The 89 
resultant recombinant was predominantly HAdV-B11 with some elements of HAdV-B3, and has 90 
progressed into clinical trials as a novel cancer therapeutic(13, 14).  HAdV-D26, is a replication deficient 91 
vector and the basis of the Ad26.ZEBOV vaccine against Ebola virus, currently under evaluation in the 92 
PREVAIL and PREVAC studies(15, 16). 93 
Many species D adenoviruses have previously been evaluated for their potential as vaccines, gene 94 
therapies, and oncolytic viruses(1, 5, 9, 11). One with particularly low seroprevalence rates is HAdV-D49. 95 
In a cohort of 100 Belgian individuals only 2% had HAdV-D49 positive sera, whilst no pre-existing 96 
immunity against HAdV-D49 was detected in 103 Scottish patients(8, 17). Prevalence is somewhat 97 
higher in sub-saharan Africa with 22% of 200 patients presenting neutralising antibodies (nAbs), 98 
highlighting significant geographical variation in seroprevalence(9). 99 
HAdV-D49 was first isolated from the faeces of a human with no observed disease, and later from Dutch 100 
patients(18, 19). It was then isolated from nosocomial epidemic keratoconjunctivitis infections(20, 21), 101 
but is most associated with patients who are immunocompromised due to HIV infection(22). A study of 102 
adenovirus infections in patients from the UK and Netherlands found 11 instances of HAdV-D49 103 
infection in 183 HIV positive patients (6% HAdV-D49 positive), compared to just two instances in 2301 104 
tested healthy patients (0.09% HAdV-D49 positive)(19). 105 
Previous studies suggest that HAdV-D49 may be effective as a vaccine vector. A vaccine vector based on 106 
HAdV-D49 has been evaluated previously for its ability to protect against simian immunodeficiency virus 107 
(SIV) challenge. This vector induced strong anti-SIVGag CD8+ mediated immunity to SIV, greater than the 108 
comparable HAdV-C5 based vector(23). Another study sought to exploit HAdV-D49 a gene therapy to 109 
reduce excessive smooth muscle cell proliferation in vascular conduits following bypass grafting. This 110 
study demonstrated that HAdV-D49 was efficient at infecting endothelial cells and vascular smooth 111 
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muscle cells, even after short exposure times(8). Studies in CA‘, CD , a d α -3 linked sialic acid 112 
expressing cells have previously suggested that HAdV-D49 may engage CD46 as a cellular receptor, 113 
although the effects observed were small(23). 114 
Despite these studies and the development of HAdV-D49 as a therapeutic agent, there remains little 115 
information surrounding the basic biology of HAdV-D49 and its means of cellular engagement. Here, we 116 
investigate the tropism of HAdV-D49, focussing on the fiber knob protein as the major mediator of 117 
cellular attachment, and evaluate the potential utility of a pseudotyped HAdV-C5/D49K vector to infect 118 
a range of cancer cell lines.  119 
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Results and Discussion 120 
HAdV-C5/D49K is not dependent on any known adenovirus receptor for cell entry 121 
To investigate the receptor usage of human adenovirus type 49 fiber knob protein we generated a 122 
replication incompetent HAdV-C5 vector pseudotyped with the fiber knob protein of HAdV-D49 (HAdV-123 
C5/D49K), expressing either green fluorescent protein (GFP) or luciferase as transgenes. We also 124 
produced a replication deficient HAdV-C5 based pseudotyped vector with the whole fiber protein, 125 
including both the fiber shaft and fiber knob of HAdV-D49, expressing luciferase (HAdV-C5/D49F). This 126 
pseudotyping approach is a well-established means to investigate the fiber knob in the context of a well 127 
understood, replication incompetent virus(1, 24). Using these pseudotyped vectors, we performed 128 
transduction assays in CHO cells expressing common adenovirus receptors (Figure 1). CHO-K1 cells do 129 
not express any known adenovirus receptor, whilst CHO-CAR cells express the HAdV-C5 receptor, 130 
coxsackie and adenovirus receptor (CAR), and CHO-BC1 cells express the BC1 isoform of CD46, the major 131 
receptor for species BI adenovirus, which includes HAdV-B35. 132 
The ability of HAdV-C5/D49K to transduce cell lines was compared to similar GFP expressing replication 133 
incompetent vectors HAdV-C5 and HAdV-C5/B35K, which engage CAR and CD46 as receptors, 134 
respectively(24–26). HAdV-C5/D35K was unable to transduce CHO-CAR, due to the lack of CD46, whilst 135 
HAdV-C5 transduced CHO-CAR cells efficiently due to the high levels of CAR expressed. HAdV-C5/D49K 136 
transduced CHO-CAR cells efficiently, but slightly less so (by ~20%) compared to HAdV-C5 (Figure 1A). In 137 
CHO-BC1 cells, transduction by HAdV-C5 was inefficient, due to the absence of CAR, whilst HAdV-C5/B35 138 
transduced these cells with almost 100% efficiency, due to the presence of high affinity HAdV-B35 139 
receptor, CD46. HAdV-C5/D49K demonstrated a similar ability to HAdV-C5-B35K to transduce CHO-BC1 140 
cells (Figure 1B). In CHO-K1 cells neither HAdV-C5 nor HAdV-C5/B35K were able to efficiently transduce 141 
the cells due to the absence of known adenovirus cell surface receptors. HAdV-C5/D49K, however, was 142 
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able to transduce these cells efficiently, indicating that HAdV-D49K is able to infect cells efficiently and 143 
independently of CAR or CD46 (Figure 1C), thus indicating HAdVC5/D49K engages an alternative cellular 144 
receptor. Interestingly, we also observed, in this and later experiments, that HAdV-C5/D49K was less 145 
efficient at infecting CHO-CAR cells (Figure 1A) compared to non-CAR expressing CHO cell types (Figure 146 
1B-C). These data indicate that the presence of CAR may actively reduce the efficiency of transduction of  147 
HAdVC5/D49K compared to levels of transduction in the absence of CAR in the same cell line 148 
background.  149 
At 385 amino acids in length, the native HAdV-D49 protein is significantly shorter than the equivalent 150 
HAdV-C5 fiber protein, which is 581 amino acids in length. This manifests as a naturally shorter and less 151 
flexible fiber shaft in HAdV-D49 compared to that of HAdV-C5. This shortened fiber shaft length may 152 
impact upon viral infectivity, resulting in trapping of adenoviral particles within late endosomes due to 153 
the decreased endosomolytic activity of shorter shafted adenoviral particles(27), reviewed 154 
elsewhere(28). To assess the impact of pseudotyping the entire short fiber protein from HAdV-D49 on 155 
viral infectivity, we performed similar transduction assays using CHO-K1 cells. Consistent with engaging 156 
an alternative receptor on CHO-K1 cells, the HAdV-C5/D49F whole-fiber pseudotyped vector efficiently 157 
transduced CHO-K1 cells, where HAdV-C5 was unable. Also consistent with previous observations of 158 
shorter shafted HAdVs potentially displaying reduced infectivity due to altered or less efficient 159 
intracellular trafficking post-entry, the HAdV-C5/D49F was less efficient than the k o -o l  160 
pseudotype HAdV-C5/D49K at infecting CHO-K1 cells (Figure 1D).  161 
We performed similar transduction assays using CHO-K1 and SKOV-3 ovarian cancer cells with and 162 
without pre-treatment with either heparinase or neuraminidase to determine the ability of 163 
HAdVC5/D49K to  bind heparan sulphate proteoglycans (HSPGs) or sialic acid, respectively, to mediate 164 
cellular infection (Figure 2). As a positive control for heparinase activity we compared HAdV-C5/D49K 165 
infectivity to that of HAdV-C5 in the presence and absence of coagulation factor X (FX), a blood 166 
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coagulation factor which can facilitate infection of some adenovirus by binding to the viral hexon and 167 
cellular heparan sulfate proteoglycans (HSPGs)(29). We observed in CHO-K1 and SKOV-3 cells that 168 
transduction levels of HAdV-C5 alone were poor (Figure 2A, B), but were significantly enhanced by the 169 
presence of FX, enabling cell entry through cellular HSPGs (30–32). Treatment with heparinase to cleave 170 
HSPGs reduced transduction efficiency to that of HAdV-C5 alone. HAdV-C5/D49K transduction efficiency 171 
was unaffected by treatment with heparinase (Figure 2A, B), indicating that HAdV-D49 is unlikely to 172 
utilise HSPGs for cell entry. 173 
Treatment with neuraminidase to remove cellular sialic acid did not alter the ability of any of the viruses 174 
to transduce CHO-K1 cells (Figure 2C), as we previously demonstrated to show the involvement of sialic 175 
acid in HAdV-C5/D26K infection(24). In SKOV-3 cells, removal of sialic acid actually enhanced the 176 
transduction mediated by HAdV-C5/D49K and HAdV-C5/B35K, an effect which we have previously 177 
observed by neuraminidase treatment in SKOV-3 cells (Figure 2D)(24, 33, 34). This effect could be a 178 
result of the removal of sialic acid enhancing non-specific charge-based interactions between the cell 179 
surface and viral capsid. Regardless, these data do not support a role for sialic acid in HAdV-C5/D49K cell 180 
infection. 181 
The transduction affinity of HAdV-C5/D49K in the experiments in Figure 2 was noticeably weaker than in 182 
the CHO cell experiments (Figure 1). This is due to the methodology used in each experiment. In the 183 
transduction experiments (Figure 1), cells were incubated with virus at 37°C for three hours. For studies 184 
evaluating the role of sialic acid and HSPGs, cells were pre-treated with enzyme for one hour at 37°C. 185 
Then virus was then incubated with cells on ice for one hour following enzymatic digestion to prevent 186 
repair and reconstitution of the cleaved heparin/sialic acid. This incubation on ice (and for a shorter 187 
period of time) likely decreases viral internalisation during the absorption step, seemingly more 188 
profoundly for HAdV-C5/D49K than for the HAdV-C5 suggesting weaker binding at the cell surface or a 189 
comparatively low frequency of cell surface receptor. 190 
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Desmoglein 2 (DSG2) is the other remaining well-established adenovirus receptor. DSG-2 is described to 191 
interact with species BII adenovirus, including HAdV-B3K, via low affinity, avidity dependent 192 
mechanism(35). We investigated whether HAdV-D49K might also interact with DSG2 by utilising surface 193 
plasmon resonance (SPR), which we have previously used to establish a 66.9µM affinity between DSG2 194 
and HAdV-D3K(36). HAdV-D49K had no detectable affinity for DSG2 (Figure 3A), an unsurprising finding 195 
as DSG2 has never been observed as a receptor for any adenovirus outside of species B. 196 
HAdV-D49 fiber knob can interact with CAR, but does not require it for cell entry 197 
We also used SPR to further probe the binding affinity of HAdV-D49K, and a mutant version, HAdV-198 
D49.KO1.K, for CD46 and CAR. This HAdV-D49.KO1.K mutant, harbours the KO1 mutations S408E and 199 
P409A in the fiber knob AB loop, previously shown to ablate CAR binding in HAdV-C5K(37). The structure 200 
of the HAdV-D49.KO1.K fiber knob is also presented (Table 1, PDB 6QPO)(38). As predicted, we did not 201 
observe binding between either fiber knob protein and CD46. However, we did observe HAdV-D49K 202 
binding to CAR with a detectable 0.19µM affinity which was ablated by the KO1 mutation (Figure 3A). 203 
We performed IC50 binding studies using recombinant HAdV-D49K protein on CHO-CAR and CHO-BC1 204 
cells and assessed the ability of the recombinant fiber knob protein to inhibit the binding of anti-CAR or 205 
CD46 antibodies, respectively (Figure 3B). HAdV-D49K was able to block anti-CAR antibody binding to 206 
CHO-CAR cells in a dose dependent manner (IC50 = 0.16μg/105 cells, Figure 3B). However, no IC50 could 207 
be derived by using HAdV-D49K to block CD46 on CHO-BC1 cells, where HAdV-D49K was unable to 208 
achieve more than 20% inhibition of antibody binding, suggesting weak or incidental CD46 interactions 209 
(Figure 3B). Therefore, these data support the findings from SPR and transduction experiments that 210 
HAdV-D49K may bind CAR with low affinity, but does not bind CD46. 211 
Our earlier findings indicated that HAdV-C5/D49K is not dependent upon CAR for cell entry (Figure 1), 212 
however our in vitro biological inhibition and SPR assays demonstrate CAR binding affinity (Figure 3A, B). 213 
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We further investigated this finding by performing transduction blocking experiments using the CAR 214 
engaging HAdV-C5 and HAdV-C5/D49K with recombinant fiber knob protein of each virus in CHO-CAR 215 
and CHO-K1 cells. As predicted, pre-incubation of CHO-CAR cells with recombinant HAdV-C5K efficiently 216 
inhibited HAdV-C5 infection (Figure 3C), whilst blocking with HAdV-D49K inhibited infection by HAdV-C5 217 
by approximately 50% (Figure 3D). Infecting CHO-CAR cells with HAdV-C5/D49K pseudotype and 218 
attempting to block using HAdV-C5K (Figure 3E) or HAdV-D49K (Figure 3F) did not significantly inhibit 219 
transduction efficiency. Finally, infection of CHO-K1 cells by HAdV-C5/D49K and blocking with HAdV-C5K 220 
did not significantly inhibit transduction efficiency (Figure 3G), whilst blocking with HAdV-D49K reduced 221 
transduction efficiency by approximately 50% (Figure 3H).  222 
These data confirm that HAdV-D49K is capable of binding to CAR, albeit at approximately 1000x lower 223 
affinity than HAdV-C5(36), but in a manner able to inhibit HAdV-C5 binding. These data confirm HAdV-224 
C5/D49K is capable of entering cells though a non-CAR mediated pathway, since HAdV-C5K cannot 225 
inhibit HAdV-C5/D49K transduction in CHO-CAR cells (Figure 3E). Interestingly, HAdV-C5/D49K was able 226 
to inhibit its own viral infection only in the absence of CAR (Figure 3H). 227 
One potential explanation for this activity is that the unknown alternative receptor to CAR has a lower 228 
affinity for HAdV-D49K than CAR. Therefore, in the presence of CAR the recombinant fiber knob would 229 
be sequestered on the higher affinity CAR receptor leaving the alternative receptor free to interact with 230 
the virus. A low affinity receptor would also, likely, depend upon avidity, so might not be observed with 231 
single trimers of HAdV-D49K; a similar effect has previously been observed with HAdV-B3K and 232 
DSG2(39) and CD46(40). This is supported by the observation what HAdV-D49K cannot transduce cells as 233 
efficiently when incubated on ice in the absence of CAR, while HAdV-C5 and HAdV-C5/B35K, which form 234 
high affinity receptor interactions, are unencumbered (Figure 2). 235 
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HAdV-D49K may bind cells through a charge dependent mechanism 236 
To investigate other closely related HAdV with homologous fiber-knob proteins we performed a BLASTp 237 
search using the HAdV-D49K amino acid sequence. This search revealed that the HAdV-D30K protein is 238 
highly homologous to HAdV-D49K, differing in just 4 amino acid residues (Figure 4A). 239 
We solved the crystal structures of HAdV-D30K (Figure 4B) and HAdV-D49K (Figure 4C). Diffraction data 240 
collection statistics for these structures are provided in Table 1. We demonstrate that structurally, 241 
HAdV-D30K and HAdV-D49K are highly homologous (RMSD = 0.292Å2). Residue 338 is not surface 242 
exposed on either fiber knob protein and is likely to be functionally homologous (HAdV-D49 = 243 
Isoleucine338, HAdV-D30 = Valine338). However, the remaining 3 residue differences, E238K, G330A, 244 
and Q331K (HAdV-D30K  D49K) are surface exposed at the apex of each fiber knob monomer (Figure 245 
4D, E). The E238K and Q331K substitutions have opposing charges. 246 
We investigated the transduction efficiency of HAdV-C5/D30K compared to HAdV-C5/D49K, HAdV-C5, 247 
HAdV-C5.KO1, and HAdV-C5/D49.KO1.K in CHO-CAR (Figure 4F) and CHO-K1 cells (Figure 4G). HAdV-C5 248 
infected CHO-CAR cells efficiently whilst the CAR-binding ablated KO1 mutant version did not, whilst 249 
HAdV-C5/49K and the corresponding mutant HAdV-C5/49KO1.K infected CHO-CAR cells with similar 250 
efficiency as observed for HAdV-C5/D49K in Figure 1A. HAdV-C5/D30K infected CHO-CAR cells with 251 
approximately 40% efficiency (Figure 4F). In CHO-K1 cells HAdV-C5/D49K and the KO1 mutant were the 252 
only viruses which achieved efficient transduction. Surprisingly, given the high homology to HAdV-253 
C5/D49K, the HAdV-C5/D30K pseudotype was inefficient in transducing CHO-K1 cells (<5% GFP+, Figure 254 
4G). 255 
This profound difference in transduction efficiency between HAdV-C5/D30K and HAdV-C5/D49K must be 256 
dependent upon the 3 surface exposed amino acid differences. We investigated the effect of the 257 
opposing charges at residue substitutions 238 and 331 (Figure 4A-E) by modelling the electrostatic 258 
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surface potential of the two fiber knob proteins, based on our crystal structures (Figure 5). The surface 259 
potential maps reveal that whilst structural homology was high, they present radically different 260 
electrostatic surface potential distributions. HAdV-D30K is significantly more acidic (pI = 5.57) than 261 
HAdV-D49K (pI = 8.26) (Figure 5). 262 
Thus, it seems probable that the interaction with the unknown cell surface receptor requires basic 263 
electrostatic potential. This is commensurate with the previous inference that its receptor is likely to be 264 
low affinity, as electrostatic interfaces are often observed to be less stable than their ionic counterparts. 265 
It is possible that the electrostatic potential differences explain the reduced transduction affinity 266 
observed in HAdV-C5/D30K compared to HAdV-C5/D49K in CHO-CAR cells. Should the strong charge on 267 
HAdV-D49K be opposed to that on the surface of CAR, this could enhance the interaction stability and 268 
therefore overall virus affinity. It seems unlikely that the residue substitutions themselves would 269 
strongly influence CAR affinity as they occur at the apex of the fiber knob, an area which is not critical 270 
the CAR interface(1). 271 
HAdV-C5/D49K is able to efficiently infect a large range of cancer cell lines 272 
Given HAdV-C5/D49K infects cells independently of known adenovirus receptors we hypothesised that it 273 
may form the basis of an efficient vector for cancer virotherapy applications. We therefore compared its 274 
transduction efficiency to that of HAdV-C5 in panels of pancreatic, breast, oesophageal, colorectal, 275 
ovarian and lung cancer cell lines (Table 2). 276 
In pancreatic cancer cell lines HAdV-C5/D49K was consistently more efficient at cellular transduction 277 
than HAdV-C5. This improved activity ranged between 4.2x more efficient in MiaPaCa2 cells to 210.9x 278 
more efficient in BxPc3 cells. The most effectively transduced cell line was Panc10 cells, producing 279 
7.2x106 RLU/mg of fluorescence, compared to the least efficient at just 4.0x105 RLU/mg in Panc0403 280 
cells. This suggests that the large differences between HAdV-C5/D49K and HAdV-C5 transduction levels 281 
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are likely due to the variability in the expression of CAR. A similarly broad range of different relative 282 
infection efficiencies were observed in the breast cancer cell lines studied. In MCF7 cells and BT20 cells 283 
HAdV-C5/D49K was nearly 500-fold more efficient at transducing the cells due to these cells expressing 284 
low levels of CAR, with consequent poor levels of HAdV-C5 mediated transduction (Table 2). 285 
DLD-1 colorectal cancer cells were efficiently transduced by both HAdV-C5 and HAdV-C5/D49K vectors, 286 
at 5.0x106 and 6.0x106 RLU/mg respectively. This is the only cell line where no significant difference in 287 
infectivity was observed. A427 lung carcinoma cells are the only line where HAdV-C5 mediated cellular 288 
transduction was more efficient than HAdV-C5/D49K (0.6x). Whilst HAdV-C5/D49K transduced A427 cell 289 
very efficiently (7.2x106 RLU/mg) HAdV-C5 achieved unusually high transduction efficiency (1.2x107 290 
RLU/mg) (Table 2). Therefore, this result is not due to inefficient HAdV-C5/D49K transduction, but 291 
unusually efficient HAdV-C5 transduction. 292 
Conclusions 293 
Previous experiments using whole HAdV-D49 virus concluded that it utilises CD46 as its primary cellular 294 
receptor(23). The data described, generated using either purified HAdV-D49 fiber knob protein or a 295 
pseudotyped HAdV-C5/D49K vector, clearly demonstrate CD46 to be implausible as a receptor for HAdV-296 
D49.  297 
We demonstrate that the HAdV-D49 fiber knob has a weak affinity for CAR, although it is not dependent 298 
upon this interaction to mediate efficient cell entry, and in fact the presence of CAR may inhibit cellular 299 
transduction. In support of this we show a mutant vector, HAdV-C5/D49.KO1.K, containing mutations 300 
within the fiber knob domain which ablate CAR affinity, retained the ability to efficiently transduce cells 301 
in the absence of any detectable binding to CAR. Based on the low efficiency by which HAdV-C5/D49K 302 
transduced cells when absorbed on ice and the observation that HAdV-D49K is only capable of inhibiting 303 
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HAdV-C5/D49K transduction in the absence of CAR, we tentatively suggest that the unknown receptor is 304 
likely to be bound with weak affinity and virus attachment may be avidity dependent. 305 
Regardless of the mechanism of interaction this study strongly suggests there is an as yet unknown 306 
adenovirus receptor or mechanism of cell entry which mediates efficient transduction of a broad range 307 
of cell lines. This is demonstrated by its ability to efficiently infect every cell line tested, throughout this 308 
study. The weakest observed transduction was in Panc0403 cells where it achieved 4.0x105 RLU/mg of 309 
luminescence. Whilst this is not a particularly strong transduction efficiency, it is still significantly higher 310 
(33.0x, P<0.05) than that of HAdV-C5. It is likely, therefore, that the HAdV-C5/D49K vector described 311 
here may be useful in biotechnology applications to efficiently express proteins in difficult to transduce 312 
cell lines.  313 
HAdV-C5/D49K represents a highly efficient gene transfer vehicle which is not restricted by any known 314 
adenovirus tropism. It possesses a broad range of infectivity and has potential as both a laboratory 315 
reagent, for the transient expression of transgenes, and as a therapeutic vaccine or oncolytic virus. For 316 
oncolytic applications, it is likely that further refinement, such as the introduction of mutations known 317 
to confer tumour selective replication, such as dl24 mutation(41–43) or the use of tumour specific 318 
promoters such as hTERT(44) or survivin(45) to drive transgene therapeutic expression selectively within 319 
tumour cells will be necessary to ensure tight tumour selectivity.  320 
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Materials and Methods 321 
GFP transduction assay 322 
Adherent cells were seeded into a Nunc delta surface 96-well cell culture plate (ThermoFisher) at a 323 
density of 5x104 ells/ ell i  μl of ell ulture edia a d left to adhere o er ight at ˚C i  a % CO2 324 
hu idified at osphere. Media as re o ed a d ells ashed t i e ith μl of PB“. Virus as added 325 
at the desired concentration i  μl of seru  free ‘MPI  a d i u ated for hrs. The irus 326 
containing media was then removed and replaced with complete cell culture media and the cells 327 
i u ated for a further hrs. Cell ulture edia as the  re o ed, the ells ashed t i e ith μl 328 
of PB“, tr psi ised i  μl of . % Tr psi -EDTA (Gibco), and dissociated by pipetting. The trypsinised 329 
cells were transferred to a 96-well V- otto  plate Ther oFisher , eutralised ith μl of o plete 330 
cell culture media, and pelleted by centrifugation at 1200RPM for 3mins. Supernatant was removed, the 331 
ells ashed o e i  μl of PB“, a d resuspe ded i  μl of % PFA (PBS containing 2% w/v 332 
parafor aldeh de  a d i u ated at ˚C for i s. Cells ere agai  pelleted, ashed t i e i  μl 333 
PB“, the  resuspe ded i  μl PB“ prior to a al sis  flo to etr . 334 
Samples were analysed by flow cytometry on Attune NxT (ThermoFisher), voltages were set prior to 335 
each experiment, for each cell type, using an uninfected cell population treated identically. Data was 336 
analysed using FlowJo v10 (FlowJo, LLC), gating sequentially on singlets, cell population, and GFP 337 
positive cells. Levels of infection were defined as the percentage of GFP positive cells (% +ve), and/or 338 
Total Fluorescence (TF), defined as the percentage of GFP positive cells multiplied by the median 339 
fluorescent intensity (MFI) of the GFP positive population. These measures are distinct in that % +ve 340 
describes the total proportion of cells infected, and TF describes the total efficiency of transgene 341 
delivery. 342 
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Luciferase transduction assay 343 
Luciferase infectivity assays were performed using the luciferase assay system kit (Promega). Cells were 344 
seeded into a Nunc delta surface 96-well cell culture plate (ThermoFisher) at a density of 2x104 345 
ells/ ell i  μl of ell ulture edia a d left to adhere o er ight at ˚C i  a % CO2 humidified 346 
atmosphere. Media was removed a d ells ashed o e ith μl of PB“. Lu iferase tra sge e 347 
encoding replication incompetent viruses were added to the wells at the required titre in 200µl of serum 348 
free RMPI 1640 and incubated for 3hrs. The virus containing media was then removed and replaced with 349 
complete cell culture media and the cells incubated for a further 45hrs. Cell culture media was then 350 
re o ed, the ells ashed t i e ith μl of PB“, a d ere the  l sed i  μl of ell ulture l sis 351 
buffer (part of the Promega kit) diluted to 1x in ddH2O. The plate was then frozen at - ˚C. 352 
After tha , μl of l sate fro  the ell ulture plate i ed the  as tra sferred to a hite Nu  -353 
i ro ell plate Ther oFisher  a d μl of lu iferase assa  reage t Pro ega Kit  added. Lu iferase 354 
activity was then measured in relative light units (RLU) by plate reader (Clariostar, BMG Labtech). Total 355 
protein concentration was determined in the lysate using the Pierce BCA protein assay kit 356 
(Thermofisher) according to the manufacturers protocol, absorbance was measured on an iMark 357 
microplate absorbance reader (BioRad). 358 
Relative virus infection was determined by normalising the measured luciferase intensity to the total 359 
protein concentration (RLU was divided by protein concentration). This gave a final infectivity readout in 360 
RLU/mg of protein. 361 
Blocking of virus infection with recombinant fiber knob protein 362 
This assay was also performed using the luciferase assay system kit (Promega). Cells were seeded into a 363 
Nunc delta surface 96-well cell culture plate (ThermoFisher) at a density of 2x104 ells/ ell i  μl of 364 
ell ulture edia a d left to adhere o er ight at ˚C i  a % CO2 humidified atmosphere. Media was 365 
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removed and cells washed 2x with 200µl of cold PBS and the plate cooled on ice. 20pg/cell of 366 
recombinant adenovirus fiber knob was added to each well in 200µl of cold PBS and incubated on ice in 367 
a ˚C old roo  for hr. Media as the  re o ed a d lu iferase tra sge e e odi g repli atio  368 
incompetent viruses added to the necessary wells at the required titre in 200µl of cold serum free RMPI 369 
 a d i u ated o  i e i  a ˚C old roo  for hr. The irus o tai i g edia as the  re o ed a d 370 
replaced with complete cell culture media and the cells incubated for a further 45hrs under normal cell 371 
culture conditions. From this point forward the assay is identical to the GFP and luciferase transduction 372 
assays. 373 
Heparinase and Neuraminidase transduction assays 374 
Cells were seeded at a density of 5x104 cells/well in a flat bottomed 96 well cell culture plate and 375 
i u ated o er ight at °C to adhere. Cells ere ashed t i e ith µl of PB“. μl of 376 
eura i idase fro  Vi rio Cholera, Merk  at a o e tratio  of U/ l, or μl of Hepari ase III 377 
(from Flavobacterium heparinum, Merck) at a concentration of 1U/ml was diluted in serum free media, 378 
added to the appropriate wells, and incubated for 1hr at 37°C. Cells were cooled on ice and washed 379 
twice with 200µl of PBS. Green Fluorescent Protein (GFP) expressing, replication incompetent viruses 380 
were added to the appropriate wells at a concentration of 5000 viral particles per cell, in 100µl of serum 381 
free media, at 4°C, and incubated on ice for 1hr. Serum free media alone was added to uninfected 382 
control wells. Cells were washed twice with 200µl of cold PBS, complete media added (DMEM, 10% FCS) 383 
and incubated for a further 48hrs at 37°C. Cells were then trypsinised and transferred to a 96 well V-384 
bottom plate, washed twice in 200µl of PBS and fixed in 2% paraformaldehyde containing PBS for 385 
20mins before wash, and resuspension in 200µl of PBS. 386 
Samples were analysed by flow cytometry on Attune NxT (ThermoFisher), voltages were set prior to 387 
each experiment, for each cell type, using an uninfected cell population treated identically. Data was 388 
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analysed using FlowJo v10 (FlowJo, LLC), gating sequentially on singlets, cell population, and GFP 389 
positive cells. Levels of transduction were defined as the percentage of GFP positive cells (% +ve), and/or 390 
Total Fluorescence (TF), defined as the percentage of GFP positive cells multiplied by the median 391 
fluorescent intensity (MFI) of the GFP positive population. These measures are distinct in that % +ve 392 
describes the total proportion of cells infected, and TF describes the total efficiency of transgene 393 
delivery. 394 
Surface Plasmon Resonance 395 
Surface plasmon resonance was performed, in triplicate, as previously described, using recombinant 396 
HAdV-D49K protein(36). Approximately 5000 RU of Recombinant Human Desmoglein-2 Fc Chimera 397 
Protein (R&D Systems, Catalogue number 947-DM-100) was amine coupled to a CM5 sensor chip at a 398 
slow flow-rate of  μl/ i  to e sure u ifor  distri utio  o  the hip surfa e. 399 
Competition Inhibition Assay 400 
Competition inhibition assays of antibody binding to cell surface receptors were performed as previously 401 
described(36). 402 
Generation of recombinant fiber knob proteins 403 
Recombinant fiber knob proteins used in transduction inhibition, antibody blocking, and crystallisation 404 
experiments were produced as previous described(24, 36). Briefly, pQE-30 vectors containing the 405 
sequence of the relevant fiber knob protein, spanning from 13 amino acids preceding the TLW motif to 406 
the stop codon, were transformed into SG13009 E.coli harbouring the pREP-4 plasmid. 1L of these E.coli 407 
were grown to OD0.6 and protein expression induced with a final concentration of 0.5mM IPTG. E.coli 408 
were harvested by centrifugation and resuspended in 50ml l sis uffer   M Tris, pH . ,   M 409 
NaCl, % /  NP ,   g/ l L soz e,   M β-mercaptoethanol). Sample was then loaded onto a 410 
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HisTrap FF Crude column and eluted by imidazole. Fractions determined to contain protein of interest 411 
were then concentrated to <1ml total volume and purified by size exclusion chromatography using a 412 
Superdex 200 10/300 GL Increase column. 413 
Fiber knob protein crystallisation and structure determination by X-Ray 414 
crystallography 415 
HAdV-D49K, HAdV-D49.KO1.K, and HAdV-D30K were crystallised in the same manner as previously 416 
described(24, 36). Both HAdV-D49K and HAdV-D49.KO1.K crystals formed in 0.1M MMT, 25% w/v 417 
PEG1500, whilst HAdV-D30K crystallised in 0.1M SPG, 25% w/v PEG 1500. All crystals formed in 2-7 days 418 
in sitting drop format. Data collection statistics are described in Table 1 and the structures were solved 419 
by molecular replacement using PDB 6FJN. 420 
Calculation of electrostatic surface potentials and pIs 421 
Electrostatic surface potential and isoelectric points were calculated at pH 7.2 using the PDB2PQR Server 422 
(V 2.1.1)(46) as previous described(24). 423 
RMSD calculation, sequence alignment, and imaging of crystal structures 424 
Alignments were performed using the Clustal Omega multiple sequence alignment algorithm and 425 
visualised with BioEdit(47, 48). ‘M“D al ulatio s ere perfor ed usi g the alig  o a d i  P MOL 426 
2.0, which was also used to visualise protein structures(49). 427 
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Figure Legends: 577 
Figure 1: HAdV-C5/D49K infection is not dependent upon CAR or CD46. Transduction assays were 578 
performed in Chinese Hamster Ovary (CHO) cells stably expressing CAR (A), CHO-BC1 cells, stably 579 
expressing human CD46 isoform BC1 (B), or CHO-K1 cells, which do not express any known adenovirus 580 
fiber-knob receptors (C, D). Cells were infected with 5,000 viral particles per cell of replication deficient 581 
HAdV-C5, HAdV-C5/B35K, or HAdV-C5/49K expressing a GFP transgene (A-C), or HAdV-C5, HAdV-C5/49K 582 
or HAdV-C5/49F expressing luciferase (D). n=3 error is ±SD 583 
Figure 2: HAdV-C5/49K transduction is not dependent upon HSPGs, sialic acid bearing glycans or 584 
Desmoglein 2 (DSG2). Transduction assays were performed in CHO-K1 (A) or SKOV-3 (B) cells with and 585 
without heparinase pre-treatment. As a positive control, HAdV-C5 assays also were performed also in 586 
the prese e of μg/ l of FX. Transduction assays were performed with the indicated viral vectors in 587 
CHO-K1 (C) or SKOV-3 (D) cells which had been pre-treated with neuraminidase to cleave cell surface 588 
sialic acid. Cells were infected with 5,000 viral particles per cell of replication deficient HAdV-C5, HAdV-589 
C5/B35K, or HAdV-C5/49K expressing a GFP transgene, n=3 error is ±SD. *= P<0.05, **= P<0.01, ***= 590 
P<0.005, , ****= P<0.001 based on non-parametric Mann-Whitney test. 591 
Figure 3: HAdV-D49K interacts with CAR but is not dependent upon it as an entry receptor. Surface 592 
plasmon resonance to detect potential interactions between HAdV-D49K or HAdV-D49.KO1.K and CAR, 593 
CD46 and DSG2 (A). Antibody binding inhibition assays to assess the ability of recombinant HAdV-D49K 594 
to inhibit antibody binding to CHO-CAR or CHO-BC1 cells (B). Blocking of HAdV-C5 mediated 595 
transduction was studied by preincubation of CHO-CAR cells with HAdV-C5K (C) or HAdV-D49K (D). 596 
Blocking of HAdV-C5/D49K mediated transduction was studied by preincubation of CHO-CAR cells with 597 
HAdV-C5K (E) or HAdV-D49K (F). Blocking of HAdV-C5/D49K mediated transduction was studied by 598 
preincubation of CHO-K1 cells with HAdV-C5K (G) or HAdV-D49K (H). Cells were infected with 5,000 viral 599 
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particles per cell of replication deficient HAdV-C5 or HAdV-C5/D49K expressing a luciferase transgene, 600 
with and without blockade by 20μg of recombinant HAdV-C5 or HAdV-D49 fiber knob protein. n=3 error 601 
is ±SD. *= P<0.05, **= P<0.01 based on non-parametric Mann-Whitney test. 602 
Figure 4: HAdV-D49K differs from HAdV-D30K in only three surface exposed amino acids but 603 
demonstrates radically altered cellular tropism. Clustal Ω sequence alignment (numbering based on 604 
whole fiber sequence) of HAdV-D30K and HAdV-D49K (A). Viewed from the apex down the three fold 605 
axis, as if towards the viral capsid, the crystal structures of HAdV-D30K (B) and HAdV-D49K (C) reveal 606 
that three of these residues are surface exposed. These residues can be seen projecting into the solvent 607 
from loops on the apex of HAdV-D30K (D) and HAdV-D49K (E), residue numbers and names correspond 608 
to the fiber-knob protein depicted in that frame. Sticks representing residues belonging to HAdV-D30K 609 
and HAdV-D49K are seen in pink and green, respectively. Transduction assays were performed to assess 610 
tropism of HAdV-C5/D30K, HAdV-C5/D49K and HAdV-C5/D49.KO1.K in CHO-CAR cells (F) and CHO-K1 611 
cells (G). Cells were infected with 5,000 viral particles per cell of replication deficient HAdV-C5 or HAdV-612 
C5/D49K expressing a luciferase transgene, with and without blockade by 20μg of recombinant HAdV-C5 613 
or HAdV-D49 fiber knob protein. 614 
Figure 5: The residue differences between HAdV-D30K and HAdV-D49K effect the surface electrostatic 615 
potential of the fiber knob. The calculated pI of HAdV-D30K and HAdV-D49K is differ as a result of the 616 
residue changes, which are shown as green sticks as they occur in that fiber knob protein. The calculated 617 
electrostatic surface potential at pH7.35 is projected on a -10mV to +10mV ramp (Red to Blue). HAdV-618 
D49K is seen to have much more basic potential around the apex where the residue substitutions are. 619 
Table 1: Single crystal diffraction data collection statistics for fiber knob crystal structures determined in 620 
this study. 621 
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Table 2: Comparison of transduction of various cancer cell lines by HAdV-C5 and HAdV-C5/D49K. *= 622 
P<0.05, **=P<0.01, ***=P<0.001, ****=P<0.0001, ns=not significant based on Student t-test. 623 
 624 
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Table 1: Single crystal diffraction data collection and refinement statistics for fiber knob crystal 
structures determined in this study. 
PDB Entry 6STU – HAdV-D30K 6QPN – HAdV-D49K 6QPO – HAdV-D49K.KO1 
Data Collection   
Diamond Beamline I03 I03 I03 
Date 18/04/2019 2017-02-27 2017-02-27 
Wavelength 0.95372 0.97628 0.97628 
Crystal Data   
Crystallisation Conditions 
0.1M SPG, 25% w/v PEG 
1500 
0.1M MMT [Malic acid, 
MES, Tris], pH8.0, 25% 
w/v PEG 1500 
0.1 M MMT [Malic acid, MES, 
Tris], pH 8.0, 25 % w/v PEG 
1500 
pH 6.0 8.0 8.0 
a,b,c (Å) 63.35, 87.36, 217.86 106.83, 56.28, 115.70 105.17, 55.99, 116.03 
 90, 90, 90 90.00, 112.95, 90.00 90.0, 112.47, 90.0 
Space group P 21 21 21 P 1 2 1 P 1 2 1 
Resolution (Å) 2.39 – 54.76 2.74 – 106.54 2.45 – 57.07 
Outer shell 2.39 – 2.45 2.74 – 2.81 2.45 - 2.51 
R-merge (%) 0.116 (1.376) 8.2 (163.3) 9.7 (127.4) 
R-meas (%) 0.134 (1.583) 9.7 (191.0) 11.4 (149.9) 
CC1/2 0.998 (0.623) 0.981 (0.400) 0.994 (0.491) 
I / σ(I) 11.2 (1.4) 6.8 (1.0) 9.2 (1.2) 
Completeness (%) 100.0 (100.0) 99.1 (98.9) 99.3 (99.3) 
Multiplicity 7.5 (7.8) 3.7 (3.7) 3.7 (3.7) 
Total Measurements 365,880 (28,110) 122,219 (9,179) 168,773 (12,231) 
Unique Reflections 48,897 (3,589) 33,350 (2,461) 45,958 (3,349) 
Wilson B-factor(Å2) 48.7 68.9 59.9 
Refinement Statistics   
Total number of refined 9,623 9,083 9,356 
R-work reflections 46,478 31,740 43,733 
R-free reflections 2,348 1,609 2,225 
R-work/R-free (%) 21.4 / 26.3 21.1 / 25.9 19.4 / 23.5 
rms deviations   
Bond lengths (Å) 0.009 0.009 0.012 
Bond Angles (°) 1.767 1.688 1.928 
1Coordinate error 0.288 0.369 0.264 
Mean B value (Å2) 60.2 94.3 80.5 
Ramachandran Statistics   
Favoured/allowed/Outliers 
1090 / 107 / 10 1004 / 104 / 35 1065 / 87 / 36 
% 90.3 / 8.9 / 0.8 87.8 / 9.1 / 3.1 89.7 / 7.3 / 3.0 
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Table 2: Comparison of transduction of various cancer cell lines by HAdV-C5 and HAdV-C5/D49K. *= 
P<0.05, **=P<0.01, ***=P<0.001, ****=P<0.0001, ns=not significant 
Cancer Type 
Cell 
Line 
Name 
Level of HAdV-C5 
Infection 
(RLU/mg total 
protein) 
Level of HAdV-
C5/D49K Infection 
(RLU/mg total 
protein) 
Change in infectivity 
(Fold change HAdV-
C5/D49K divided by 
HAdV-C5 RLU/mg) 
Statistical 
Significance 
(p value) 
Pancreatic 
Adenocarcinoma, 
derived from acitic 
metastasis 
ASPC1 3.9E+04 1.2E+06 30.7 ** 
Pancreatic 
Adenocarcinoma 
BXPC3 1.2E+04 2.5E+06 210.9 ** 
Pancreatic 
Adenocarcinoma 
Panc10 1.0E+05 7.2E+06 69.2 **** 
Pancreatic 
Adenocarcinoma, 
derived from splenic 
metastasis 
SW1990 9.6E+04 1.1E+06 11.3 **** 
Pancreatic 
Adenocarcinoma 
MIA 
PaCa2 
3.4E+05 1.4E+06 4.2 ** 
Pancreatic 
Adenocarcinoma, 
derived from liver 
metastasis 
Suit2 6.0E+04 1.3E+06 22.2 * 
Pancreatic Ductal 
Adenocarcinoma 
PANC 
0403 
1.2E+04 4.0E+05 33.0 * 
Pancreatic Ductal 
Adenocarcinoma, 
Derived from liver 
metastasis 
CFPAC-
1 
1.8E+04 1.1E+06 62.0 *** 
Pancreatic Ductal 
Adenocarcinoma 
PT45 3.9E+05 2.0E+06 5.1 ** 
Breast Carcinoma BT-20 1.8E+03 8.6E+05 481.2 * 
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Breast Ductal 
Carcinoma 
BT-474 6.5E+03 1.4E+05 21.8 * 
Breast 
Adenocarcinoma, 
derived from brain 
metastasis 
MDA-
MB-361 
2.2E+05 1.5E+06 6.7 ** 
Breast 
Adenocarcinoma, 
derived from plural 
effusion metastasis 
MDA-
MB-231 
3.3E+04 1.5E+05 4.6 * 
Breast 
Adenocarcinoma, 
derived from plural 
effusion metastasis 
MCF7 1.3E+04 6.6E+06 497.3 *** 
Large Lunge Cell 
Carcinoma 
NCI-
H460 
2.1E+05 3.9E+06 18.8 * 
Lung Carcinoma A427 1.2E+07 7.2E+06 0.6 * 
Lung Carcinoma A549 2.8E+06 6.9E+06 2.5 *** 
Esophageal Squamous 
Cell Carcinoma 
Kyse-30 6.3E+05 1.4E+07 22.4 *** 
Colorectal 
Adenocarcinoma, 
Duke's Type C 
DLD-1 6.0E+06 5.0E+06 0.8 ns 
Ovarian 
Adenocarcinoma 
SKOV-3 9.1E+05 7.7E+06 8.5 ** 
Gastric tubular 
adenocarcinoma 
MKN28 2.6E+05 2.0E+07 76.9 *** 
Gastric adenocarcinoma MKN45 3.1E+04 2.2E+06 71.0 *** 
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